Drug Discovery

In this GEN webinar, sponsored by Carterra, we will demonstrate how modern day high-throughput surface plasmon resonance (HT-SPR™) has facilitated a paradigm shift in antibody screening, enabling higher information content assays to be conducted earlier in the research pipeline to streamline lead selection. This essentially combines screening and detailed characterization in the same step, condensing months of work into days.

Companies agree to co-develop Pieris’ preclinical dual- checkpoint inhibitor PRS-332 and up to seven other immuno-oncology bispecific drug candidates

In the future, production systems will become smaller. The production environment will move to be more flexible and compartmentalized. R&D workflows might become more integrated. Manufacturing execution systems may end up combined with bioprocessing tools to connect, control, and automate standard unit operations. The role of suppliers will become even more important with the development of new disposable technologies, among other advances.

Diabetes formulation that consists of GLP1 recombinantly fused to a thermosensitive biopolymer may triple duration of single-injection efficacy

J&J disclosed it is in talks with the NIH’s National Institutes of Allergy and Infectious Diseases (NIAID) to accelerate the schedule for its COVID-19 vaccine Phase III trial, depending on the outcome of the Phase I/IIa study and approval from regulators.

Combined company will let customers share data on more than 500 medical conditions.

Insys Therapeutics shares plunged 74% in early market trading this morning after the company warned it may file for Chapter 11 bankruptcy protection as...

Free of toxic and hallucinogenic side effects, ibogaine-inspired tabernanthalog (TBG) shows promise as a potential treatment for the detrimental effects of stress on the brain. After receiving a single dose of TBG, mice exposed to unpredictable mild stress had their anxiety levels reduced. Also, deficits in sensory processing and cognitive flexibility were reversed.

SeraCare Life Sciences acquired Kirkegaard & Perry Laboratories (KPL), a provider of antibodies and related reagents for the diagnostic and life sciences markets.

Kite plans to modify genes through Sangamo's zinc finger nuclease technology, in order to develop autologous and allogeneic next-generation cell therapies for different cancers